AI Article Synopsis
- AGR2 is a protein linked to cancer that promotes metastasis and is highly expressed in various cancers.
- Etravirine, a drug typically used for HIV treatment, was found to induce the degradation of AGR2, reducing cancer cell proliferation, migration, and invasion in lab tests.
- In mouse models, combining etravirine with paclitaxel effectively slowed down cancer progression and metastasis, suggesting its potential as a treatment for ovarian cancer.
Article Abstract
Anterior gradient protein 2 homolog (AGR2), an endoplasmic reticulum protein, is secreted in the tumor microenvironment. AGR2 is a member of the disulfide isomerase family, is highly expressed in multiple cancers, and promotes cancer metastasis. In this study, we found that etravirine, which is a non-nucleoside reverse transcriptase inhibitor, could induce AGR2 degradation via autophagy. Moreover, etravirine diminished proliferation, migration, and invasion in vitro. Moreover, in an orthotopic xenograft mouse model, the combination of etravirine and paclitaxel significantly suppressed cancer progression and metastasis. This drug may be a promising therapeutic agent for the treatment of ovarian cancer.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC8777939 | PMC |
| http://dx.doi.org/10.3390/ijms23020944 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!